BEING ALIVE: February 1995 Mark Katz, MD, and reported by Jim Stoecker
Researchers recently did a follow up study of people who were part of the original Phase I study of ddI. For those who entered the original study with less than 100 T-cells, the four year survival rate was 8%. Of those who entered the Phase I study with between 100 and 300 T-cells, however, 80% survived at least four years from the start of the study. This does not mean that ddI alone accounted for the survival rate. Certainly we need to consider other factors such as OI prophylaxis. Nonetheless, a four year survival rate of 80% for people with an original CD4 count of 300 or less is very heartening news.
950201
BA950203
AEGiS is made possible through unrestricted grants from Roxane Laboratories, the National Library of Medicine, and donations from users like you. Always watch for outdated information. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.
This information is designed to support, not replace, the relationship that exists between you and your doctor.